Advaxis Inc. submitted a Special Protocol Assessment request to the FDA to initiate detailed design discussions for a phase III clinical study of ADXS-HPV for the treatment of high-risk, locally advanced cervical cancer.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
